EyePoint Announces Participation at Upcoming Investor Conferences
Rhea-AI Summary
EyePoint (Nasdaq:EYPT) announced management participation in three upcoming investor conferences focused on ophthalmology and healthcare.
Fireside chats are scheduled for May 26, June 3, and June 9, 2026, and will be available via live webcast and archived replay on the company's investor relations website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – EYPT
On the day this news was published, EYPT gained 1.03%, reflecting a mild positive market reaction. Argus tracked a peak move of +14.5% during that session. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $1.07B at that time.
Data tracked by StockTitan Argus on the day of publication.
WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:
- Stifel 2026 Virtual Ophthalmology Forum
Forum: Fireside Chat
Date: May 26, 2026
Time: 9:00 am ET
- Jefferies Global Healthcare Conference
Forum: Fireside Chat
Date: June 3, 2026
Time: 4:55 p.m. ET - Goldman Sachs 47th Annual Global Healthcare Conference
Forum: Fireside Chat
Date: June 9, 2026
Time: 11:20 a.m. ET
A webcast and subsequent archived replay of each fireside chat may be accessed via the Investors section of the Company website at www.eyepoint.bio.
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media:
Helen O’Gorman
FTI Consulting
helen.ogorman@fticonsulting.com
